See more : Textainer Group Holdings Limited (3T70.F) Income Statement Analysis – Financial Results
Complete financial analysis of Serina Therapeutics Inc (SER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Serina Therapeutics Inc, a leading company in the industry within the sector.
You may be interested
- NPC Co., Ltd. (004250.KS) Income Statement Analysis – Financial Results
- Satsuma Pharmaceuticals, Inc. (STSA) Income Statement Analysis – Financial Results
- Fabryki Mebli FORTE S.A. (FTE.WA) Income Statement Analysis – Financial Results
- China Communications Services Corporation Limited (CUCSF) Income Statement Analysis – Financial Results
- Goodpatch, Inc. (7351.T) Income Statement Analysis – Financial Results
Serina Therapeutics Inc (SER)
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 142.00K | 500.00K | 3.04M | 54.00K | 1.73M | 1.40M | 1.40M | 1.67M |
| Cost of Revenue | 171.00K | 145.00K | 150.00K | 1.28M | 998.50K | 841.00K | 685.00K | 911.00K |
| Gross Profit | -29.00K | 355.00K | 2.89M | -1.23M | 729.50K | 555.00K | 719.00K | 755.00K |
| Gross Profit Ratio | -20.42% | 71.00% | 95.06% | -2,272.22% | 42.22% | 39.76% | 51.21% | 45.32% |
| Research & Development | 603.00K | 1.57M | 3.80M | 3.58M | 5.35M | 5.35M | 5.27M | 7.87M |
| General & Administrative | 0.00 | 1.29M | 1.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.33M | 1.29M | 1.30M | 5.60M | 7.94M | 5.65M | 3.87M | 5.62M |
| Other Expenses | 0.00 | -265.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.93M | 2.77M | 4.67M | 9.18M | 13.29M | 11.00M | 9.14M | 13.49M |
| Cost & Expenses | 10.10M | 2.77M | 4.67M | 10.46M | 14.29M | 11.84M | 9.82M | 14.41M |
| Interest Income | 0.00 | 1.76K | 10.86K | 0.00 | 29.00K | 116.00K | 0.00 | 0.00 |
| Interest Expense | 4.90M | 15.88K | 3.09K | 404.00K | 0.00 | 0.00 | 12.00K | 25.00K |
| Depreciation & Amortization | 131.00K | 132.00K | 131.00K | 1.26M | 951.00K | 535.00K | 682.00K | 845.00K |
| EBITDA | -9.78M | -2.60M | -1.59M | -8.74M | -11.61M | -7.20M | -7.74M | -11.89M |
| EBITDA Ratio | -6,887.32% | -494.65% | -52.23% | -16,948.15% | -671.76% | -709.89% | -550.93% | -713.93% |
| Operating Income | -9.96M | -2.27M | -1.63M | -10.41M | -12.56M | -10.45M | -8.42M | -12.74M |
| Operating Income Ratio | -7,014.08% | -454.07% | -53.68% | -19,272.22% | -726.79% | -748.21% | -599.50% | -764.65% |
| Total Other Income/Expenses | -4.85M | -411.74K | 366.81K | 8.00K | 323.00K | 2.71M | 1.78M | -4.62M |
| Income Before Tax | -14.81M | -2.68M | -1.26M | -10.40M | -12.24M | -7.73M | -6.64M | -17.36M |
| Income Before Tax Ratio | -10,430.28% | -536.42% | -41.61% | -19,257.41% | -708.10% | -553.80% | -472.72% | -1,041.72% |
| Income Tax Expense | -8.00K | -250.04K | 3.09K | 466.00K | 148.00K | -229.00K | -57.00K | -1.86M |
| Net Income | -14.80M | -2.68M | -1.26M | -10.87M | -12.15M | -7.50M | -6.58M | -15.49M |
| Net Income Ratio | -10,424.65% | -536.42% | -41.61% | -20,120.37% | -703.36% | -537.39% | -468.66% | -929.89% |
| EPS | -13.72 | -2.49 | -1.17 | -10.14 | -11.47 | -7.56 | -6.46 | -15.21 |
| EPS Diluted | -13.72 | -2.49 | -1.17 | -10.14 | -11.47 | -7.56 | -6.46 | -15.21 |
| Weighted Avg Shares Out | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M | 1.02M |
| Weighted Avg Shares Out (Dil) | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M | 1.02M |
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing...
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its...
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has...
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced that Steve Ledger, Interim Chief Executive Officer of Serina, will present at the...
Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended June 30, 2024 and provided business highlights.
Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug delivery technology, today announced that Randall Moreadith, MD, Ph.D., Chief Development Officer, will present at the 4th...
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation
HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Dr. Srini Tenjarla as the new Senior Vice President of...
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended March 31, 2024 and provided business highlights.
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
- Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development - HUNTSVILLE, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company focused on developing its proprietary POZ PlatformTM...
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases, today announced the closing of its previously announced...
Source: https://incomestatements.info
Category: Stock Reports